Plasma Fractionation Market Report 2026 Market Outlook Supported By A Forecast 10.4% CAGR

The plasma fractionation sector has witnessed significant expansion recently, driven by advances in technology and growing demand for plasma-derived therapies. As the healthcare industry evolves, this market is set to experience further growth, supported by innovation and increased global collaboration. Here's an in-depth look at the current market landscape, key players, driving forces, and emerging trends shaping its future.

Plasma Fractionation Market Size and Growth Outlook
The plasma fractionation market has seen rapid growth, with its valuation expected to increase from $34.14 billion in 2025 to $37.63 billion in 2026, representing a compound annual growth rate (CAGR) of 10.2%. This upward trend during the historical period has been fueled by rising demand for immunoglobulins, a higher incidence of hematological disorders, technological progress in fractionation methods, expanded hospital and clinical infrastructure, and greater awareness regarding plasma-derived treatments. Moving forward, the market is projected to grow even faster, reaching $55.85 billion by 2030 at a CAGR of 10.4%. Factors contributing to this future expansion include the growing adoption of precision medicine, integration of artificial intelligence in plasma manufacturing, increased global biopharmaceutical partnerships, more investments in plasma collection centers, and the development of innovative plasma-based therapies. Key trends anticipated in the coming years include the evolution of advanced fractionation technologies, diversification of biopharmaceutical products, improved quality control and regulatory adherence, growth of contract manufacturing organizations (CMOs/CDMOs), and optimization of plasma supply chains.

Download a free sample of the plasma fractionation market report:
https://thebusinessresearchcompany.com/sample_request?id=11432073&type=smp&name=Plasma%20Fractionation%20Market%20Report%202026&utm_source=OpenPR&utm_medium=Paid&utm_campaign=Oct_PR

Key Drivers Stimulating Plasma Fractionation Market Expansion
The increasing adoption of precision medicine is playing a major role in driving the plasma fractionation market forward. Personalized therapies that target specific diseases require plasma-derived products, which boosts demand for efficient fractionation processes. Additionally, the integration of AI technology in manufacturing enhances production capabilities and quality assurance, making plasma therapies safer and more effective.

Another significant driver is the expansion of global biopharmaceutical collaborations, which facilitates resource sharing and innovation across borders. Investment in plasma collection centers is also rising, improving the availability of raw materials required for plasma fractionation. Simultaneously, the development of new plasma-derived treatments expands the range of therapeutic options, supporting sustained market growth.

View the full plasma fractionation market report:
https://www.thebusinessresearchcompany.com/report/plasma-fractionation-global-market-report?utm_source=OpenPR&utm_medium=Paid&utm_campaign=Oct_PR

Leading Companies Making an Impact in Plasma Fractionation
Several key players dominate the plasma fractionation industry, including Baxter International Inc., Bio Products Laboratory Limited, Biotest AG, CSL Limited, Grifols S. A, ADMA Biologics Inc., Green Cross Corporation, Hualan Bioengineering Inc., Intas Pharmaceuticals Ltd., Japan Blood Products Organization, Kedrion S. P. A., Kamada Ltd., LFB Biomedicaments S. A. S, Octapharma AG, Sanquin Plasma Products B. V., Shanghai Raas Blood Products Co. Ltd., Takeda Pharmaceutical Company, Terumo BCT, China Biologic Products Holdings Inc., China National Biotec Group, Emergent BioSolutions Inc., Bharat Serum Vaccines Limited, Plasma Therapeutics, Prothya Biosolutions B. V., BioPharma Plasma LLC, and BioLife Plasma Services LP.

In a notable recent development, France-based biopharmaceutical firm LFB acquired Amber Plasma, a plasma collection company based in the Czech Republic, in May 2024 for an undisclosed sum. This acquisition is intended to strengthen LFB's plasma collection network across Europe and enhance its capacity for producing plasma-derived therapies.

Technological Innovations Boosting Plasma Fractionation Market Growth
Industry leaders are increasingly adopting high-tech processes to transform donated human plasma into critical medicines more efficiently and safely. For example, in March 2023, CSL Behring, a German-based company, opened a new $470 million plasma fractionation plant equipped with cutting-edge technology designed to improve both efficiency and safety during plasma processing. This facility not only helps meet the growing demand for life-saving plasma-derived medications but also incorporates advanced automation and self-cleaning systems to reduce contamination risks, thereby improving patient safety.

Primary Segments Within the Global Plasma Fractionation Market
The plasma fractionation market is segmented based on product, application, and end-user categories.

By product, the market includes immunoglobulins, coagulation factors, albumin, and protease inhibitors. In applications, it covers fields such as immunology, hematology, neurology, critical care, hemato-oncology, and rheumatology. End users mainly comprise hospitals and clinics, clinical research laboratories, and academic institutions.

Further subcategories break down as follows:
- Immunoglobulins include Intravenous Immunoglobulin (IVIG) and Subcutaneous Immunoglobulin (SCIG).
- Coagulation factors are divided into Factor VIII, Factor IX, and Prothrombin Complex Concentrates (PCC).
- Albumin is classified into Human Albumin and Bovine Serum Albumin (BSA).
- Protease inhibitors consist of Alpha-1 Antitrypsin (AAT) and C1 Esterase Inhibitor (C1-INH).

These detailed segments enable precise market analysis and support targeted development within the plasma fractionation industry.

New additions to our 2026 reports:

• Market attractiveness scoring and analysis
• Total addressable market (TAM) analysis
• Company scoring matrix graphics and tables
• Excel-based forecasting dashboards
• Market hotspots infographics
• Key technologies and future trend analysis
• Updated graphics and tables

Reach out to us:
The Business Research Company: https://www.thebusinessresearchcompany.com/,
Americas +1 310-496-7795,
Europe +44 7882 955267,
Asia & Others +44 7882 955267 & +91 8897263534,
Email us at info@tbrc.info.

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Learn More About The Business Research Company
With over 30,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.Our flagship product, the Global Market Model (GMM), is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.